a PTP-1B inhibitor......
Monday June 10, 2:00 pm Eastern Time
Press Release
SOURCE: Wyeth
Wyeth Discontinues Clinical Program for Its Type-2 Diabetes Candidate
MADISON, N.J., June 10 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE - News) announced today that it is discontinuing clinical development of PTP-112. The decision was based on unsatisfactory Phase II clinical efficacy, as well as the occurrence of dose-limiting side effects among several trial participants.
The Company has notified all clinical trial investigators and has provided instructions regarding patient follow-up. The Company also has informed the Food and Drug Administration (FDA).
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
SOURCE: Wyeth
from an old Wyeth article......
We wanted to get at the root of the problem and find a way to overcome insulin resistance. Our search for potential therapeutic targets focused on the PTPase family of enzymes because they are directly involved in the process of 'turning off' insulin receptors. With the help of biotechnology, we validated one specific target enzyme, PTP-1B. We then created a humanized, recombinant version of the protein to use with a high-throughput screen, rapidly testing tens of thousands of compounds to find one that would inhibit the action of this enzyme. Upon finding a promising candidate, we refined it using technologies such as x-ray crystallography and molecular modeling along with creative medicinal chemistry to enhance the structure of the compound for greater efficacy. The result of that work was PTP-112, a small molecule with a novel therapeutic action that keeps the insulin receptor 'turned on' and prolongs the body's responses to insulin. PTP-112 is scheduled to begin Phase II clinical trials during 2001. |
